Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENHERTU vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Unresectable or metastatic HER2-positive breast cancer after prior anti-HER2-based regimen in metastatic setting,Metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer after prior chemotherapy in metastatic setting,Unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after prior trastuzumab-based regimen,HER2-positive non-small cell lung cancer with activating HER2 mutation after prior systemic therapy,HER2-positive solid tumors (tumor agnostic) after prior systemic therapy and no satisfactory alternative
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
DXd, the released payload, is primarily metabolized by CYP3A4.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Trastuzumab deruxtecan: Approximately 99% bound to plasma proteins (primarily to albumin).
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Approximately 10–12 L (approx. 0.14–0.17 L/kg for a 70 kg adult), indicating distribution primarily in vascular space.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Not applicable; administered intravenously (100% bioavailability).
Intravenous administration yields 100% bioavailability.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). No data for severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 4.4 mg/kg. Child-Pugh C: Not recommended.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy not established; no recommended dose.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment. Monitor for toxicity, especially in patients aged ≥65 years due to limited data.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY. Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have occurred. Monitor for signs and symptoms of ILD and withhold, dose reduce, or permanently discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise patients of these risks.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Interstitial lung disease/pneumonitis,Left ventricular ejection fraction (LVEF) reduction,Neutropenia,Fever, infection, or thrombocytopenia,Embryo-fetal toxicity
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
None listed.
None known.
No specific food interactions are known; however, ENHERTU may cause nausea, vomiting, and diarrhea. Patients should avoid heavy, spicy, or fatty foods if gastrointestinal side effects occur and maintain adequate hydration.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of trastuzumab deruxtecan to pregnant rats during organogenesis resulted in embryofetal toxicity including decreased fetal weight and increased fetal malformations at exposures below the recommended human dose based on AUC. Due to the potential for genotoxicity and inhibition of rapidly dividing cells, there is a high teratogenic risk, particularly during the first trimester. During second and third trimesters, fetal growth restriction and oligohydramnios may occur due to HER2 receptor inhibition, although the deruxtecan component primarily drives toxicity. Effective contraception should be used during treatment and for at least 7 months after the last dose.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
There are no data on the presence of trastuzumab deruxtecan in human milk, its effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 7 months after the last dose. The M/P ratio is unknown.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
There are no specific dose adjustment guidelines for ENHERTU during pregnancy. The recommended dose is 5.4 mg/kg as an intravenous infusion every 3 weeks. Pregnancy may alter drug pharmacokinetics due to increased plasma volume, reduced albumin, changes in hepatic metabolism and renal clearance. However, no pharmacokinetic studies have been conducted in pregnant women. Therefore, the standard dosing should be used with caution, and clinical judgment should be applied based on maternal and fetal monitoring. Dose reductions or delays may be considered if significant toxicities (e.g., ILD, neutropenia, hepatic impairment) occur. Due to the high risk of fetal harm, use in pregnancy is not recommended unless the maternal benefit justifies the risk.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Monitor for interstitial lung disease (ILD) and pneumonitis; withhold ENHERTU for grade 1 ILD and permanently discontinue for grade 2 or higher. Assess left ventricular ejection fraction (LVEF) before and during treatment; withhold for any grade of reduction. Premedicate with antiemetics per institutional guidelines. Do not substitute with trastuzumab or ado-trastuzumab emtansine.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Report new or worsening cough, shortness of breath, or fever immediately as these may be signs of lung problems.,Notify your doctor of any nausea, vomiting, diarrhea, or constipation as these can be managed with medications.,Avoid pregnancy during treatment and for 7 months after last dose; use effective contraception.,Do not breastfeed during treatment and for 1 month after last dose.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENHERTU vs COLUMVI, answered by our medical review team.
ENHERTU is a Antineoplastic Agent that works by Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENHERTU and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENHERTU is: 5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENHERTU and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENHERTU is classified as Category C. Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.